TP53 and cancer: Answering whether heterogeneous oligomers are on- or off-pathway intermediates and investigating those involved in cancer through different methods, such as cryo-EM and super resolution microscopy, will definitely point oncogenic mutants of p53 as potential targets for anticancer therapy [11].